Everything tagged "biotech" across the TickerSpark archives.
GSK is leaning on specialty medicines, Shingrix, and a strong HIV franchise to offset declines in legacy categories. The stock looks fairly valued with modest upside, making it more of a steady Hold than a high-conviction buy.
Corcept has a strong commercial base, a newly approved oncology product, and raised 2026 guidance, but the stock still screens as expensive. The report lands on a Hold as earnings pressure and execution risk offset the long-term growth story.
Regeneron earns a Buy on strong Dupixent momentum, rising free cash flow, and a valuation that still leaves room for upside. EYLEA erosion remains the key offset, but the pipeline and capital returns support the medium-term case.
Danaher is seeing better operating momentum across Life Sciences, Diagnostics, and Biotechnology, but the stock still trades at a premium that limits upside. The report keeps a Buy rating with fair value set at $225.
Medpace is still delivering strong revenue, margin, and cash flow growth, but softer bookings and a rich valuation keep the stock in Hold territory. The business quality is high, yet the current setup looks better on pullbacks than at full price.
Biogen’s business has stabilized, with growth products and LEQEMBI helping offset legacy MS pressure. The stock still looks reasonably priced for a selective Buy as cash flow and mix improve.
Biogen’s selloff looks backward-looking. A newly approved home-start LEQEMBI formulation and fresh real-world stability data make the Alzheimer’s story easier to scale, not harder to believe.
Moderna’s latest drop looks more like regulatory panic than a broken thesis. With an Aug. 5 FDA decision now in sight and the flu program still under active review, the selloff looks overdone.
BridgeBio has evolved from a pipeline biotech into a commercial-stage rare-disease story, led by explosive Attruby sales and a late-stage pipeline. The stock still carries meaningful balance-sheet risk, but the launch momentum is real.
Moderna’s latest surge looks earned, not speculative. Science Day gave the market a concrete post-COVID roadmap, and the August 5 flu decision gives MRNA a real catalyst investors can actually underwrite.
Abivax just posted the kind of Phase 3 efficacy biotech investors wait years to see, and the stock still got cut nearly in half because the market fixated on a safety overhang. That risk is real, but a 44.1% one-day collapse looks more like panic repricing than a fair read on a drug that delivered 50%+ remission in maintenance.
Seven biotech stocks ranked by investment quality — Regeneron, Vertex, and Axsome all make the list, with the top two spots saved for the countdown's finish.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the GeneratorCancel anytime